A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension

This study will evaluate the efficacy and safety of either bimatoprost 0.01% ophthalmic solution (Lumigan®) alone or bimatoprost 0.01% ophthalmic solution (Lumigan®) and brimonidine tartrate 0.1% ophthalmic solution (Alphagan® P) in combination in patients previously treated with latanoprost 0.005% ophthalmic solution monotherapy who require additional intraocular pressure (IOP) lowering medication.

Inclusion Criteria:

• Ocular hypertension or glaucoma in at least 1 eye
• Visual acuity of 20/100 or better in both eyes

Exclusion Criteria:

• Corneal refractive laser surgery (LASIK, LASEK, PRK, RK) in the study eye(s)
• Intraocular or glaucoma surgery in the past 3 months